Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulzer to start trials on bone growth protein:

This article was originally published in Clinica

Executive Summary

Sulzer Medica will begin US clinical trials to examine whether its bone growth protein can repair bone loss associated with periodontal disease. Consisting of a mixture of naturally occurring bone growth factors in a collagen matrix, Ne-Osteo, a bone morphogenic protein (BMP), promotes bone growth. Sulzer Orthopedics Biologics is working with Sulzer Calcitek to develop applications of the Ne-Osteo BMP technology for dental use. Sulzer expects its market in dentistry to grow to $300 million within the next ten years.

You may also be interested in...



Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Spain Lists Certain OTCs As 'Essential' In Fight Against COVID-19

Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.

Mylan And Lupin Get EU Etanercept Nod

Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.

Topics

UsernamePublicRestriction

Register

MT081733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel